CTOR Stock Overview

Focuses on the development of novel targeted oncology therapies. More details

CTOR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 96.5% below our estimate of its fair value

Earnings are forecast to grow 58.01% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($70M)

My Notes

Capture your thoughts, links and company narrative

Citius Oncology, Inc. Competitors

e-therapeutics

OTCPK:ETXP.F

US$76.0m

Genelux

NasdaqCM:GNLX

US$77.4m

Quince Therapeutics

NasdaqGS:QNCX

US$78.3m

Unicycive Therapeutics

NasdaqCM:UNCY

US$71.0m

Price History & Performance

Summary of share price highs, lows and changes for Citius Oncology
Historical stock prices
Current Share Price	US$0.98
52 Week High	US$49.00
52 Week Low	US$0.85
Beta	-0.21
1 Month Change	15.01%
3 Month Change	-41.67%
1 Year Change	-91.03%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-90.29%

Recent updates

Shareholder Returns

	CTOR	US Biotechs	US Market
7D	-10.9%	-3.8%	-2.7%
1Y	-91.0%	-2.6%	23.4%

Return vs Industry: CTOR underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: CTOR underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is CTOR's price volatile compared to industry and market?
CTOR volatility
CTOR Average Weekly Movement	20.3%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: CTOR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CTOR's weekly volatility has decreased from 37% to 20% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Leonard Mazur	n/a

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York

Citius Oncology, Inc. Fundamentals Summary

How do Citius Oncology's earnings and revenue compare to its market cap?
CTOR fundamental statistics
Market cap	US$69.74m
Earnings (TTM)	-US$19.52m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.6x

P/E Ratio

Is CTOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTOR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$19.52m
Earnings	-US$19.52m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.27
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CTOR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 22:44
End of Day Share Price	2024/12/23 00:00
Earnings	2024/06/30
Annual Earnings	2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Citius Oncology, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Okunewitch	Maxim Group

Citius Oncology NasdaqCM:CTOR Stock Report